Merck Says Keytruda Didn't Meet Primary Endpoint in Keynote-119 Breast Cancer Study
20 Mai 2019 - 11:24PM
Dow Jones News
By Stephen Nakrosis
Merck & Co. Inc. (MRK) on Monday said results from a Phase 3
KEYNOTE-119 trial evaluating Keytruda as monotherapy for some
breast cancer patients didn't meet its pre-specified primary
endpoint of superior overall survival compared to chemotherapy.
The company said the study evaluated Keytruda as monotherapy for
the second- or third-line treatment of patients with metastatic
triple-negative breast cancer.
Dr. Roy Baynes, senior vice president and head of global
clinical development, chief medical officer, Merck Research
Laboratories, said "While we are disappointed by the outcome of
this monotherapy trial, we are continuing to study Keytruda in
earlier stages of the disease and in combination with chemotherapy
to address the unmet medical need of patients with triple negative
breast cancer."
Merck said the drug's safety profile was consistent with that
observed in previous studies of patients treated with Keytruda
monotherapy and no new safety concerns were identified.
Results will be presented at an upcoming medical meeting, Merck
said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 20, 2019 17:09 ET (21:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024